Clinical Trial Update: The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis [Phase 3]

View source ↗

Summary

Phase 3 ASCEND trial evaluating TMB-001 for recessive X-linked ichthyosis and autosomal recessive congenital ichthyosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Congenital Ichthyosis
• Recessive X-linked Ichthyosis

Drugs mentioned

• TMB-001

Snippet

Sponsor: Timber Pharmaceuticals Inc. | Conditions: Ichthyosis | Phase 3 | Status: COMPLETED | Results posted: 2025-11-17